DE10259508A1 - Agent giving a repletion effect and weight loss contains a ginseng-containing material and a volume-expanding material which is insoluble or difficultly-soluble in gastric or bodily fluids - Google Patents

Abstract

An agent giving a repletion effect and weight loss contains (a) a ginseng-containing material; and (b) volume expanding material which is insoluble or difficultly-soluble in gastric or bodily fluids. An Independent claim is also included for production of the agent by introducing (A) onto (B) under pressure and at an elevated temperature.

Description

Object of the present invention is a means of creating a satiety effect and reducing weight, that especially for the Use in diet programs suitable.

Numerous attempts have been made on medication Get rid of unnecessary fat accumulations in the human body to dismantle or prevent their formation. There are z. B. so-called appetite suppressants, the body to suggest an aversion to food in a biochemical way to attempt. Some of these remedies have considerable harmful side effects.

In addition to the numerous known diet proposals it also mechanical and electromechanical means with which a targeted fat loss or muscle building. However, the effect of such funds is very doubtful.

From the DE 4025912 a means for oral administration is known which consists of a container which is detachable in the stomach and releases the contents. This is filled with a substance that increases its volume in the stomach after its release, thereby suggesting a feeling of satiety in the body. The disadvantage of this saturant is that there is a risk of intestinal obstructions.

Are also off DE 199 42 417 Sponge-like preparations with stably cross-linked compounds are known, which increase their volume in the stomach and thus cause a feeling of satiety. However, the production of these preparations requires additional process steps to introduce stable cross-links.

Because of the ever increasing health awareness however, is a further improvement in means of generating a saturation effect of high medical and economic relevance.

Object of the present invention is an improved oral intake available too make that a higher Stomach dwell time is known as a means of its kind and thereby a more effective satiety effect leads. It should also help reduce weight while regulating it of cholesterol may be appropriate because obesity is usually with high cholesterol accompanied. Furthermore simple manufacture from inexpensive raw materials is desirable, that have no health risks. Furthermore, should the agent well tolerated and in addition to the "passive" function of the saturation effect also actively support weight loss while doing so if possible do not reduce the well-being of those taking the drug.

In addition, the remedy should unite Immune stimulation and strengthening while the weight loss phase.

This object is achieved by a Means for producing a saturation effect and for weight loss containing at least one contained in ginseng Active ingredient and one in gastrointestinal fluids and / or body fluids insoluble or hardly soluble, volumenvergrößerndes Material solved.

Active ingredient in the sense of the invention are all substances with a pharmaceutical or biological effect to understand.

Ginseng is a herbaceous, anemone-like Araliacee (Panax ginseng), which grows wild and in the mountain forests of East Asia is also grown and the root u. a. Contains steroid derivatives. To the previously isolated ingredients include sitosterol and more than 10 triterpene glycosides ginsenosides. The ginsenoids are a group of glycosides of tetracyclic triterpenes (sapogenins) from the ginseng root (Panax ginseng): 24-Dammaren-3,12,20-triol, the (3a, 12b, 20S) form is called Betula film triol and the diastereomeric (3b, 12b, 20S) form protopanaxadiol. Protopanaxatriol has an additional 6a-hydroxy group. The sugar components in these glycosides are D-glucopyranose, L-arabinopyranose, L-arabinofuranose, the D-xylofuranose and D-xylopyranose as well the L-rhamnopyranose. The ginsenosides become anti-ischemic, immunostimulating, antithrombotic (PAF antagonist.), hypoglycemic and Cholesterol-lowering properties are said. After new investigations The ginseng extract generally stimulates the protein and nucleic acid metabolism on. Furthermore, one found, among other things, an essential oil responsible for the smell of ginseng, in which a number of sesquiterpenes have been characterized. Ginseng finds mainly used as roborans and geriatric drugs (source: Römpp Lexikon Chemistry - CD Version 2.0, Stuttgart / New York: Georg Thieme Verlag 1999).

By combining the at least an active ingredient contained in the ginseng and the volume increases So material is next to the saturation effect also improves well-being as well as weight loss positive affected.

In short, ginseng is known for its health-promoting use as a universal agent. Ginseng acts as a stimulating and stimulating cardiovascular agent, as an antidepressant and as a nerve food. In addition, ginseng has a strong immunostimulatory effect, promotes the build-up of body protein, improves memory and concentration as well as mental and physical resilience. In addition, ginseng has a positive influence on adult diabetes, stimulates metabolism, regulates blood lipid levels and lowers blood pressure.

Ginseng increases adaptability and tolerance of the body across from Stress and protects against the negative effects of permanent stress. In addition, ginseng increases the physical capacity and promotes in general the building processes and provides the body with more energy; one speaks of an anabolic effect. Ginseng increases also the ability to concentrate and attention, improves thinking and memory and works against fatigue and exhaustion. Ginseng also acts on the central nervous system as needed stimulating or calming. Ginseng is able to raise blood sugar levels to lower and raise a too low blood sugar level. Also Ginseng is known for its active ingredients to work through several mechanisms Stimulate immune defense. Ginseng is also capable of important enzymes to activate in cell metabolism and the liver. This leads to a increased synthesis of DNA, RNA and important proteins. In particular, the amount reduced glutathione increased, which plays an important role in cell metabolism especially in the liver is playing. additionally cause the active ingredients contained in ginseng antioxidative, d. H. they especially prevent free radicals, which are otherwise cells damage. Ginseng is used as a support the therapy of cardiovascular diseases where he liquefies the blood, controls the blood pressure, lowers cholesterol and the heart's need for oxygen lowers and strengthens the heart muscle. Ginseng is also able to do so thanks to the active ingredients it contains To influence the blood picture, especially the stimulation the bone marrow cells known for division and blood formation. Also Ginseng is known for its respiratory functions improves and inflammation can be inhibited. additionally Ginseng is said to have a sexual stimulating effect.

In particular, the influence of im Active ingredients contained in ginseng on the immune system has been studied. It has been demonstrated that taking a standardized Ginseng extract increases the immune response to a flu shot that acidic polysaccharides of the root the production of interleukin 8 promote, the ginseng polysaccharides induce the production of interferon, phagocytosis of the reticuloendothelial system, production of antibody and promote an increase in the continent in the blood, as well as the cellular immune response (Scaglione et al, Drugs Expl. Clin. Res. 23 82), 1996: 65-72; Sonoda et al, Immunopharmacology 1998; Smolina et al, Antibiotic Khimioter 1998; Chang-Xiao et al, Ethnopharmacology 1992; Jie et al, Argenst Actions 15 (3 - 4), 1984: 386-91; Kim et al, Immunopharmacology and Immunotoxicology 12 (2), 1990: 257-76).

As active ingredients contained in ginseng all come according to the invention Substances contained in ginseng are considered. In particular fall under it the above steroid derivatives, sitosterol, ginsenoids and essential oils. As well belong plus active ingredients contained in ginseng that have not yet been isolated and / or have been characterized. These active ingredients can be made from the ginseng itself or be produced artificially. The invention also includes the use of liquid, pasty, solid, granular and powdery Preparations, extracts and partial extracts, solutions and melts of ginseng, synthetically produced ingredients of ginseng and / or their Mixtures. Natural ginseng is preferably used. It particularly preferably comes from Asia, in particular Korea, because the ginseng from there is considered the most effective.

The at least one active ingredient contained in ginseng can be applied in, on or on the agent.

In a variant of the invention, the Active ingredients contained in ginseng on the surface or part of the surface of the increases in volume Material are applied. Suitable adhesion promoters can be used for this be used.

Under volume increasing Material is understood to be a material which has a corresponding volume Conditions (see below) increased, i.e. H. changed its extent, like this B. is possible by swelling, foaming or decompression.

Fixed agents come as semi-solid or liquid Substances into consideration. These can be powders, pastes, solutions, Trade melts or foils. In the latter case, for example foil-shaped Adhesion promoter layer have adhesive properties on both sides and in this way the cohesion of the carrier material with the active ingredient Ensure layer.

By applying the active ingredients Formulation and / or the carrier material with this connecting layer a connection between if necessary compressed and volume increasing in the gastrointestinal tract support material and achieved the active ingredient-containing layer. The duration of the existing Connection hangs thereby from the solubility the substances used and contained in the connecting layer in gastric juice and / or other gastrointestinal fluids.

Furthermore, the use of filamentary or tissue-like Material conceivable by which the desired duration of the connection between carrier material and layer containing the active ingredient can be controlled. Accordingly, too an agent containing thread-like and / or as a connecting agent gewebeänhliche Fabrics object of the invention.

As adhesion promoters, preference is given to compounds which are natural, synthetic contain cal and semi-synthetic polymers. In principle, nonionic and ionic polymers come into consideration. In principle, all hot-melt adhesives and contact adhesives known from the prior art can be used, provided they are suitable for pharmaceuticals or food. In a special embodiment of the present invention, the adhesion promoter is starch derivatives, cellulose derivatives, gelatin or polysaccharides, preferably polysaccharides containing polyuronic acid, e.g. B. Polyalginates. Hypomellose, Carmellose, Metholose may be mentioned as examples.

Particularly preferred polyuronic acid-containing Polysaccharides are alginic acids and their salts (alginates). But also low ester pectins, Xanthan, tragacanth, chondroitin sulfate and all other uronic acid-containing Connections can according to the invention come.

Alginic acid is a linear polyuronic acid varying proportions of D-mannuronic acid and L-guluronic acid through β-glycosidic Bonds linked together are, wherein the carboxyl groups are not esterified. One molecule of alginic acid can from around 150 - 1050 Uronic units with the average molecular weight in a range of 30-200 kDa can vary.

The polysaccharide is alginic acid a component of the cell walls of brown algae. The proportion of alginic acid in the dry mass of Algae can make up to 40% of this. The alginic acid is obtained by alkaline extraction using methods known per se according to the prior art of the technique. The resulting powdered alginic acid is thus purely vegetable and has a high biocompatibility. she can form 300 times the amount with formation of highly viscous solutions absorb their own weight in water. In the presence of multivalent Cations form alginic acid so-called gels. The formation of alginate gels in the presence of divalent Cations such as calcium or barium are described in Shapiro I., et al. (Biomaterials, 1997, 18: 583-90). The latter is due to its toxicity for use not suitable in biomedicine. In addition to calcium chloride supplies calcium gluconate also suitable divalent cations. Generally are all physiologically harmless poly cations, especially divalent ones Cations can be used.

By means of the adhesive agent described can in addition to Active ingredients contained in ginseng also other active ingredients Formulations applied to the volume-increasing material become.

According to the invention it is therefore z. B. possible in cause of a drug the overweight to treat and at the same time symptomatic the respective symptom. For example, an antihypertensive agent can be fixed the carrier material can be applied by creating a feeling of satiety Food intake and thus the weight reduced. Because weight loss at the same time an elevated Can lower blood pressure, it comes with the use of the combination preparation described an improvement in efficacy and therapy compared to the individual dose.

On the described volume-increasing material can the active ingredients contained in ginseng and / or the other active ingredients are applied, preferably using the described Adhesion promoters. You can also the active ingredients contained in the ginseng and / or, if applicable, the others Active ingredients are applied directly if, for. B. liability mediator Have substances or adhesion-promoting under pressure at temperatures Develop properties. It is also possible to use ginseng Active substances and / or possibly the further active substances in the volume-increasing material z. B. already in the manufacture or manufacture of the carrier.

The active ingredients contained in ginseng and / or the other active ingredients can can also be applied to the carrier material in one or more layers and Z. B. be covered by a top protective layer (paint). This varnish should then change under the appropriate conditions dissolve and enable the release of the active ingredients.

The agent according to the invention using the Adhesion promoter is described after taking the agent in the stomach in enlarged material and the active ingredient-containing formulations) containing layers split. The active ingredient-containing formulations may be due to of which get into the intestine, d. H. because of this absorbed in the intestine become.

The volume-increasing material according to the invention guaranteed to develop the satiety effect required increase in volume of the Release system. Because of this, the material is larger than the opening of the gastric exit and is thus a rapid onward transport from Stomach in the intestine, i.e. H. the residence time in the stomach for the carrier material is longer than for the active ingredient layer. Due to the dwell time of the carrier material As a result, a feeling of satiety is evoked in the stomach and for the time being of staying in the stomach.

According to the invention, however, it is also possible to use different ones Combine active ingredients. So in addition to that described in the stomach soluble Adhesion promoter an adhesion promoter who is not dissolves in the stomach. Active ingredients are then applied to this adhesion promoter, which should remain in the stomach and exert their effect there.

Furthermore, according to the invention it is possible to glue together several volume-increasing pieces of material of the same or different composition. When using the adhesive that is soluble in the stomach, these materials dissolve pieces from each other. As a result, an increased saturation effect can be achieved. In such a system, the active substances can be arranged between several pieces of material by means of the adhesion promoter. When the individual pieces of material tumble apart in the stomach, the layers of active substance detach and reach the intestine to develop their effect there. If necessary, active substances can also be used which at least partially dissolve in the stomach and, where appropriate, develop their therapeutic effect there.

According to the invention, the Invention also sponge-like materials in the volume-increasing Material included, which z. B. after previous compression decompress in the stomach or under the influence of Swell up any fluid in the stomach.

Among such spongy materials are fixed according to the invention or semi-rigid elastic foams understand that from gas filled for example polyedertörmigen Cells consist of highly viscous and / or solid cell webs are limited. Both naturally occurring can be used according to the invention sponges, semi-synthetic or synthetic sponge-like structures. examples for synthetic sponge-like materials are polyurethanes, polyacrylates, Poly (meth) acrylic acid derivatives, Homo and copolymers of vinyl acetate. To the natural and semi-synthetic polymers include. a. Cellulose, cellulose ether or cellulose esters such as cellulose acetate and cellulose acetate phthalate. examples for natural Polymers are polysaccharides such as alginates, tragacanth, xanthan gum, Guar gum and its salts and derivatives. The use of chitin and of chitin derivatives is possible. In addition, substances with a fiber structure such as scleroproteins are preferred z. B. collagen, keratin, conchagens, fibroin, elastin and chitin used. About that polysaccharides which are crosslinked in a stable manner are also an object of the present invention.

The production of the sponge-like or -shaped Formations are made using methods known per se according to the state of Technology. Here, reference is made to WO 98 / EP96 / 03950, which also The subject of the present invention is. Dependent on in the simplest case, the starting material can be used a foam by blowing in, by beating, shaking, spraying or stirring in the relevant gas atmosphere be preserved. In the case of the polymers, the foam structure is due to chemical reactions. So z. B. by adding blowing agents, which at certain temperature during processing with gas formation decompose, or foamed by adding liquid solvents during the polymerization. The foaming takes place either when leaving the extrusion die, d. H. following extrusion or injection molding or in open molds. curing takes place under the for the respective chemical compound of the carrier material characteristic Conditions.

Indispensable property of the volume increasing according to the invention Materials is that it is is compressible or can increase its volume. For the selection of the carrier material is finally also essential that it swellable remains without the Cell bridges destroyed become. The compressed material also keeps in the compressed state its sponge structure.

Under physiological conditions, the compressed material can expand, for example, two to ten times, preferably four to eight times, its volume. The active substance release areas of the material enlarged under physiological conditions are, for example, 15 to 25 cm ² . In comparison, the values of the release areas according to the prior art are 0.5 to 1.5 cm ² .

In the agent according to the invention is the material available accordingly and / or while preferably in a compressed form.

The volume-increasing materials can also from dried porous Consist of gel or foam. Anionic materials are preferred Polymers used.

Anionic polymers preferred according to the invention are polysaccharides and here polysaccharides containing polyuronic acid, like alginic acids and their salts (alginates). But also low ester pectins, Xanthan, tragacanth, chondroitin sulfate and all other uronic acid-containing Connections can according to the invention come. The use of synthetic or semi-synthetic is also conceivable Cellulose derivatives, such as. B. carboxymethyl cellulose or polyacrylates.

Dried are advantageous according to the invention Gels or foams containing mixtures of anionic polymers, preferably the one above mentioned anionic Polysaccharides, particularly preferably mixtures containing polyuronic acid and low-esterified polysaccharides and especially mixtures containing salts of alginic acid and pectin.

With regard to the anionic polymers, the use of low ester pectins is also advantageous according to the invention. Pectins consist of chains of α-1,4-glycosidically linked galacturonic acid units, the acid groups of which are 20 - 80% esterified with methanol. A distinction is made between high-esterified (> 50%) and low-esterified (<50%) pectins. The molar mass varies between 10 - 500 kDa. Pectins are obtained by acidic extraction using methods known per se according to the prior art from the inner portions of citrus fruit peel, fruit pulp or sugar beet pulp. The resulting pectins (apple pectin, citrus pectin) are therefore purely vegetable and are highly biocompatible on. They can form gels while absorbing water.

Here too is the use of pectin gels in the presence of divalent cations, such as calcium or barium. The latter is also here due to its toxicity for use in biomedicine however not suitable. In addition to calcium chloride, calcium gluconate also provides suitable divalent cations. The use of magnesia salts or is also conceivable a mixture of different physiologically harmless divalent Cations.

The use according to the invention is also distinguished of pectins in an advantageous manner in that pectins have cholesterol-lowering properties. This property is Advantageous in the sense of the present invention, since being overweight usually with an elevated Cholesterol levels.

The agent according to the invention can, for example in the form of tablets, capsules, dragees, as granules or suppositories or other configurations are available. In addition, the agent according to the invention as an outer layer a coating exhibit. This can be a layer of paint or other protective layer be, which facilitates the taking of the agent according to the invention and which are only in the gastrointestinal tract, for example under influence the gastric fluid, dissolves.

The volume-increasing material according to the invention can except in the sponge form also in the form of powder. According to the invention, this includes both finely divided powders, granules, adsorbates and beadlets.

The production of the powdered volume-increasing Materials can be done in different ways. For example, for manufacturing in the form of an adsorbate in a mixer or in a fluidized bed reactor one or more carriers submitted, and then the further components are added. For the carriers it is preferably the volume-enlarging according to the invention Materials. According to the invention can be discontinuous or continuously operating mixers can be used. The carrier material or volume-increasing material may be presented together with additives. Classic examples are flight share mixers, cone screw mixers or similar Apparatuses. Alternatively, the product is mixed using a Movement of the entire container possible. Examples of this are tumble mixers, drum mixers etc. Another possibility consists in the use of pneumatic mixers. The use too of snails for mixing and / or reduction is conceivable.

The dosage or addition of im Active ingredients contained in ginseng or other active ingredients if necessary together with additives, e.g. B. on spot-on devices or nozzles. Examples of this are lances, shower heads, Single-component or multi-component nozzles, In rare cases rotating drip or atomizing devices. In the simplest case, the addition is also locally concentrated Jet possible. Alternatively, you can use the mixer first the active ingredient contained in the ginseng and / or the further active ingredient are submitted in order to then give up the volume-increasing material.

It is also possible to use the volume-increasing material in a liquid Soak ginseng active ingredient or ginseng extract etc.

The addition of the active ingredient contained in ginseng and / or the further active ingredient can be at overpressure, normal pressure or with negative pressure, counter atmosphere, preferably take place at normal pressure or negative pressure. To increase the Loading the volume-increasing Material and to minimize the influence of oxygen it cheap be the volume-increasing material containing mixer before adding the active ingredient contained in the ginseng and / or to evacuate further active ingredient and, if appropriate, with protective gas to cover.

According to the invention, powdery agents can also be produced by the spray formulation process. Here, for example, in an initial step, an aqueous solution of a protective colloid, e.g. B. gelatin and / or gelatin derivatives, and / or gelatin substitutes with the addition of the volume-increasing materials described above, and by adding the active ingredients contained in ginseng and / or other active ingredients with stirring, a dispersion is first prepared, the aqueous solution of the colloid forming the homogeneous phase represents the dispersion. Apparatuses in which such spray formulations can be produced are, for example, in the EP 0074050 B1 described.

The production of granules can can be achieved in that a mixer to increase the volume of the invention Fabrics and / or spray dried Powder as well as active ingredients and possibly active components and binders as well as aggregates compact granules are produced. As a mixer can For example, paddle mixers or flight share mixers are used become. The liquid Components can on various ways are added, e.g. B. dripped or sprayed on, so that one pasty, sticky mass arises. about suitable choice of the speed of the mixing tools and / or high-speed Knife becomes pasty The mass is broken up and compact granules are formed. Very big chunks can by Mixing tools and knives cut and fine powder on the other be agglomerated.

For example, a solution of sodium alginate in water is prepared and thickened with the addition of calcium salts. A gel or foam can be obtained by incorporating air and possibly adding surfactants. By freezing and then freeze-drying, the alginate gel or foam becomes a dry gel or tro back foam (sponge) made. The production of pectin-containing gels or foams is carried out in an analogous manner, as is the production of gels or foams containing mixtures of anionic polymers.

In addition to the addition of inorganic or organic calcium salts, such as. B. calcium chloride or calcium gluconate, it is also conceivable to use magnesium salts and mixtures of different ones physiologically harmless divalent cations.

According to the invention, the addition of salts can also physiologically safe trivalent cations, e.g. B. of soluble Aluminum salts are made. Here, the preparation of the agents according to the invention by adding soluble Aluminum salts to an aqueous solution of anionic polymers, preferably alginates and / or pectins, according to a manufacturing process of the type described above. Particularly suitable soluble Aluminum salts are aluminum chloride or aluminum sulfate. The soluble Aluminum salts can used alone or in combination.

According to the invention, in addition to the soluble Aluminum salts, which in turn are used alone or in combination can be additionally also still salts of divalent cations, such as. B. calcium or magnesium salts or their combination, in the preparation of the agents according to the invention be used.

The addition of shell layers, which are those in ginseng contained active ingredients and possibly the other active ingredients can, can after mixing the powder or granules in mixers lower speed of the mixing tools and stationary knives or in a design-related downstream mixer. The Shaping the agent according to the invention can by pressing the pasty, sticky phases during the pelletizing process through the die of an extruder.

The volume-increasing material according to the invention as well as the active ingredients contained in the ginseng and if necessary the other active ingredients can contain other auxiliary substances.

Examples include the following To understand substances, which, however, are not limiting for the present Invention are: Water-insoluble auxiliaries or mixtures thereof, such as lipids, etc. a. Fatty alcohols, e.g. B. cetyl alcohol, Stearyl alcohol and cetostearyl alcohol; Glycerides, e.g. B. Glycerol monostearate or mixtures of mono-, di- and triglycerides of vegetable oils; hydrogenated oils, such as hydrogenated castor oil or hydrogenated cottonseed oil; Waxes, e.g. Beeswax or carnauba wax; solid hydrocarbons, z. B. paraffin or earth wax; Fatty acids, e.g. B. stearic acid; certain Cellulose derivatives, e.g. B. ethyl cellulose or acetyl cellulose; polymers or copolymers, such as polyalkylenes, e.g. B. polyethylene, polyvinyl compounds, z. B. polyvinyl chloride or polyvinyl acetate, and vinyl chloride-vinyl acetate copolymers and copolymers with crotonic acid, or Polymers and copolymers of acrylates and methacrylates, e.g. B. copolymers of acrylic acid ester and methyl methacrylate, be used.

Except for the additives mentioned can they Means according to the present Invention in addition Filling, explosive, Binders, lubricants and carriers contain that have no decisive influence on the drug delivery to have. Examples include a. Concrete (alumina-silica hydrate), silica, cellulose (usually microcrystalline cellulose) or cellulose derivatives, e.g. B. methyl cellulose, Sodium carboxymethyl cellulose, sugars such as lactose, starches e.g. corn starch or derivatives thereof, e.g. Sodium carboxymethyl starch, starch paste, phosphoric acid salts, z. B. di- or tricalcium phosphate, gelatin, stearic acid or suitable salts thereof, e.g. B. magnesium stearate or calcium stearate, talc, colloidal silicon oxide and the like Excipients.

The following are examples of active substance-containing substances according to the invention Reproduced formulations from different therapeutic classes, but not limiting for are the present invention.

Examples of ACE inhibitors are: benazepril, captopril, Cilazapril, enalapril, fosinopril, lisinopril, perinodopril, quinapril, Ramipril, Trandolopril.

Examples of analeptics are: Almitrin, Amiphenazole, caffeine, doxapram, etamivan, fominobes, metamfetamine, Nicethamide, pentetrazole.

Examples of analgesics (opioids) are: Alfentanil, buprenorphine, cetobemidone, dextromoramide, dextropropoxyphene, Fentanyl, flupirtine, hydromorphone, levomethadone, levorphanol, meptazinol, morphine, Nalbuphin, oxycodone, pentazocin, pethidine, piritramide, tilidine, Tramadol.

Examples of analgesics (non-opioids) are: acetylsalicylic acid, Benzyl almondate, bucetin, ethenzamide, ketorolac, metamizole, morazone, Paracetamol, phenacetin, phenazone, propyphenazone, salicylamide.

Examples of anthelmintics are: albendazole, Diethylcarbamazine, mebendazole, praziquantel, tiabendazole.

Examples of antiallergics / antihistamines are: Anatazoline, astemizole, azelastine, bamipine, brompheniramine, buclizine, Carbinoxamine, cetririzine, chlorphenamine, clemastine, cyslizine, cyproheptadine, dimenhydramine, Doxylamine, fexofenadine, ketotifen, loratadine, mepyramine, mizolastine, Nedrocromil, oxatomide, oxomemazine, pheniramine, phenyltoloxamine, spaglumic acid, terfenadine, Triprolidine.

Examples of antiarrhythmic drugs are: ajmaline, amiodarone, Aprindine, quinidine, disopyramide, mexiletine, procainamide, propafenone, Tocainide.

Examples of antibiotics / chemotherapeutics are: Amikacin, Gentamicin, Kanamycin, Paromomycin, Sisomicin, Streptomycin Tobramycin, Chloro quin, halofantrine, hydroxychloroquine, mefloquine, proguanil, ethambutol, isoniazid, rifabutin, rifampicin, cefa cetril, cefaclor, cefadroxil, cefalexin, cefalotine, cefamandol, cefazolin, cefixim, cefotimoxim, cefotimoxim ), Cefradin, Cefsulodin, Ceftazidim, Ceftizoxim, Ceftriaxon, Cefuroxim (axetil), Latamoxef, Cinoxacin, Ciprofloxacin, Enoxacin, Nalidixic Acid, Norfloxacin, Ofloxacin, Pipemidic Acid, Rosoxaccinin, Oxoxillinhritomycin, Claroxinchrinoxin, Rhoxacinocillin, Claroxin, Critoxin , bacampicillin, benzylpenicillin, carbenicillin, Carindacillin, dicloxacillin, flucloxacillin, mezlocillin, oxacillin, Phenoxymethypenicillin, piperacillin, pivampicillin, propicillin, ticarcillin, colistin, teicoplanin, vancomycin, cotrimoxazole, Sulfametoxydiazin, doxycycline, oxytetracycline, tetracycline, atovaquone, chloramphenicol, fosfomycin, imipenem , Metronidalzol, nitrofurantoin, pentamidine, taurolidine, trime thoprim.

Examples of antidepressants are: amitripytylin, Amitriptyline oxide, clomipramine, desipramine, dibenzepine, dosulepine, Doxepin, fluoxetine, fluvoyamine, imipramine, lithium salts, maprotiline, Nomifensin, opipramol, oxitriptan, tranylcypromine, trimipramine, tryptophan.

Examples of antidiabetics / antihypoglycaemics are: Acarbose, carbutamide, chlorpropamide, glibenclamide, glibornuride, Gliclazide, glimepiride, glipizide, gliquidon, glisoxepid, glymidine, Guar, insulin, metformin, tolazamide, tolbutamide.

Examples of antidiarrheals are: difenoxin, diphenoxylate, Loperamide, petin, tannin.

Examples of antidotes are: flumazenil, Naloxone, naltrexone.

Examples of antiemetics are: alizapride, Betahistin, thiethylperazine.

Examples of anti-epileptics are: barbexaclon, Carbamazepine, ethosuximide, lamotrigine, mepacrine, mesuximide, phenobarbital, Phenytoin, Primidon, Sultiam, Trimethadione, Valproic Acid, Vigabatrin.

Examples of antifibrinolytics are: aminocaproic acid, 4- (aminomethyl) benzoic acid, tranexamic acid.

Examples of antihypertensives are: clonidine, diazoxide, Doxazosin, guanethidine, hydralazine, methyldopa, moxonidine, nitroprusside sodium, Phentolamine, prazosin, reserpine, tiamenidine, urapidil.

Examples of antihypotonic agents are: dihydroergotamine, Dobutamine, dopamine, etilefrin, norepinephrine, norfennefrin.

Examples of anticoagulants are: acenocoumarol, Dalteparin sodium, enoxaparin, heparin, heparinoids hirudin, lepirudin, Nadroparin, Parnaparin, Phenprocoumon, Reviparin, Tinzaparin, Warfarin.

Examples of antifungals are: amorolfine, amphotericin B, bifonazole, chlormidazole, ciclopiroxolamine, clotrimazole, croconazole, Econazole, fenticonalzol, fluconazole, griseofulvin, isoconazole, itraconazole, Ketoconazole, miconazole, naftifine, naystatine, omoconazole, oxiconazole, Terbinafine, terconazole, tioconazole, tolnaftate.

Examples of anti-inflammatory drugs are: acemetacin, Azapropazon, Benorilat, Bumadizon, Carprofen, Choline Salicylate, Diclofenac, Diflunisal, etofenamate, felbinac, fenbufen, fenoprofen, flufenamic acid, flurbiprofen, Ibuprofen, indomethacin, isoxicam, ketoprofen, lonazolac, mefenamic acid, meloxicam, mofebutazone, Nabumetone, naproxen, nifenazone, niflumic acid, oxyphenbutazone, phenylbutazone, Piroxicam, Pirprofen, Proglumetacin, Pyrazinobutazon, Salsalat, Sulindac, Suxibuzon, Tenoxicam, Tiaprofensäure, Tolmetin, Auranofin, Aurothioglucose, Aurothiomalate, aurothioplypeptide, chloroquine, hydroxychloroquine, Penicillamine, ademetionin, benzydamine, bufexamac, famprofazone, glucosamine, Oxaceprol.

Examples of antitussives are: benproperin, butamirat, Butetamate, clobutinol, clofedanol, codeine, dextromethorphan, dihydrocodeine, Hydrocodone, isoaminil, sodium dibunate, noscapine, oxeladine, pentoxyverine, Pholcodin, pipacetate.

Examples of appetite suppressants are: amfepramon, fenfluramine, Fenproporex, levopropylhexedrine, mazindol, mefenorex, metamfepramon, Norephedrine, norpseudoephedrine.

Examples of beta-receptor blockers are: acebutolol, Alprenolol, atenolol, betaxolol, bisoprolol, bopindolol, bupranolol, Carvedilol, Celiprolol, Labetalol, Levobunolol, Mepindolol, Metipranolol, Metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, Sotalol.

Examples of bronchospasmolytics / antiasthmatics are: Bambuterol, Carbuterol, Clenbuterol, Epinephrin, Fenoterol, Hexoprenaline, ipratropium bromide, isoetarin, orciprenaline, oxitropium bromide, Pirbuterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, Theopohylline, tolubuterol.

Examples of calcium antagonists are: Amlodipine, felodipine, isradipine, nicardipine, nifedipine, nilvadipine, Nitrendipine, nisoldipine, verapamil.

Examples of Cholagoga are: Anetholtrithion, Azintamide, chenodeoxycholic acid, dehydrocholic, Hymecromon, Piprozolin, Ursodeoxycholic acid.

Examples of cholinergics / cholinolytics are: aceclidine, acetylocholine, carbachol, cyclopentolate, distigmine, Edrophonium, Emepronium, Homatropin, Methantheline, Neostigmine, Pilocarpine, Propantheline, propiverine, pyridostigmine, tropicamide.

Examples of diuretics are: acetazolamide, amiloride, Bendroflumethiazide, bumetanide, chlorothiazide, chlorotalidone, clopamide, ethacrynic acid, Furosemide, hydrochlorothiazide, triamteren, xipamide.

Examples of blood circulation promoters Medium / nootropics are: Buflomedil, Buphenin, Dextran 40, Dihydroergotoxin, Iloprost, meclofenoxate, nicergoline, nicotinic acid, pentifylline, piracetam, Piribedil, pyritinol, tolazoline, Viquidil.

Examples of enzymes / inhibitors / transport proteins are: Antithrombin III, aprotinin, carnitine, clavulanic acid, Dornase alfa, sulbactan.

Examples of expectorants are: acetylcysteine, Ambroxol, bromhexine, carbocistein, colfosceril, surfactant (from Beef liver), surfactant (from pork lungs).

Examples of light sources are: Allopurinol, Benzbromaron, Colchicine, probenecid, sulfinpyrazone.

Examples of glucocorticoids are: betamethasone, Budesonide, cloprednol, cortisone, dexamethasone, flunisolide, fluticasone, Hydrocortisone, methylprednisolone, paramethasone, prednisolone, prednisone, prednylidene, Triamcinolone.

Examples of hemostatic agents are: Adrealon, blood coagulation factor VII, blood coagulation factor VIII, blood coagulation factor IX, blood coagulation factor XIII, carbazochrome, etamsylate, fibrinogen, collagen, menadiol, menadione, Protamine, somatostain, thrombin, thromboplastin.

Examples of pituitary / hypothalamic hormones and - inhibitors are: Argipressin, Chorionic Gonadotrophin, Desmopressin, Felypressin, Gonadorelin, Lypressin, Menotropin, Ornipressin, Quinagolid, Terlipressin, Thyrotrophin.

Examples of immunotherapeutics and cytokines are: aldesleukin, azathioprine, BCG, ciclosporin, filgrastim, interferon alfa, interferon beta, interleukin-2, muromonab-CD3, tacrolism, Thymopentin, thymostimulin.

Examples of Kardiaka are: Acetyldigitoxin, Acetylödiagoxin, Convallatoxin, Digitoxin, Digoxin, Gitoformat, Lanatosid, Meproscillarin, Metildigoxin, Pengitoxin, Peruvosid, Proscillaridin, Strophanthin, Thevetin, Amrinone, enoximone, milrinone,

Examples of coronary agents are: carbocromes, Isosorbide dinitrate, nitroglycerin, pentaerythrityl tetranitrate.

Examples of Laxantia are: bisacodyl, Dantron, docusate, glycerol, lactulose, magnesium sulfate, sodium picosulfate, Sodium sulfate, paraffinum subligiudum, phenolphthalein, castor oil, sorbitol.

Examples of liver therapeutic agents are: choline, citiolon, Myo-inositol, silymarin.

Examples of lipid-lowering agents are: Acipimox, bezafibrate, Clofibrate, Etofibrate, Fluvastin, Lovastatin, Pravastatin, Simvastin.

Examples of local anesthetics are: articaine, benzocaine, Bupivacaine, butanilicain, chloroethane, cinchocaine, cocaine, etidocaine, Fomocaine, Lidocaine, Mepivacaine, Myrtecain, Oxetacaine, Oxybuprocain, Polidocanol, Prilocaine, Procaine, Proxymetacaine, Quinisocaine, Tetracaine.

Examples of gastrointestinal agents are: Bismuth subcitrate, bromopride, garbenoxolone, cimetidine, domperidone, Famotidine, metoclopramide, nizatidine, omeprazole, proglumid, ranitidine, Roxatidine, sucralfate, sulfasalazine.

Examples of migraine drugs are: ergotamine, lisuride, Naratriptan, Pizotifen, Sumatriptan, Zolmitriptan.

Examples of muscle relaxants are: Alcuronium, Atracurium, Baclofen, Carisoprodol, Chlormezanon, Clostridiumtoxin botulinum toxin A, examples of parathyroid therapeutics / calcium metabolism regulators are: clodronic acid, Dihydrotachysterol, Glandulae parathyreoideae, pamidronic acid.

Examples of neuroleptics are: benperidol, chlorpromazine, Droperidol, flyeanzine, haloperidol, melperon, promethazine, zuclopenthixol.

Examples of Parkinson's drugs are: amantadine, Benserazide, benzatropine, biperiden, bornaprine, bromocriptine, cabergoline, Carbidopa, Diphydroergocriptin, Levodopa, Metixen, Pergolid, Pramipexol, Ropinirol, Tolcapone.

Examples of psychostimulants are: amfetaminil, Deanol, Fencamfamin, Fenetyllin, Kavain, Methylphenidate, Pemolin, Prolintane.

Examples of thyroid therapeutics are: carbimazole, Glandulae thyreoideae, iodine, iodide, levothyroxine, liothyronine, methylthiouracil, Perchlorate, prolonium iodide, propylthiouracil, radio iodine, thiamazole.

Examples of sedatives / hypnotics are: Amobarbital, chloral hydrate, clomethiazole, glutethimide, hexobarbital, Methaqualon, methyprylon, pentobarbital, scopolamine, secbutabarbital, Secobarbital, vinylbital, zolpidem, zopiclone.

Examples of sex hormones are: chlorotrianisen, Clomiphene, clostebol, cyproterone, drostanolone, epimestrol, estradiol, Estriol, estrone, ethinylestradiol, flutamide, fosfestrol, conjugated Estrogens, medroxyprogesterone, mesterolone, mestranol, metenolone, Methyltestosterone, nandrolone, oxymetholone, polyestradiophosphate, Quinestrol, stanozolol, testosterone.

Examples of antispasmodics are: atropine, Butylscopolamine, flavoxate, glycopyrronium, mebeverin, methylscopolamine, Oxybutynin, Tiropramid, Trospiun.

Examples of platelet aggregation inhibitors are: abciximab, acetylsalicylic acid, Dipyridamole, ticlopidine.

Examples of transquilizers are: alprazolam, bromazepam, Brotizolam, Buspirone, Camazepam, Chlordiazepoxide, Clobazam, Clonazepam, Clorazepate, clotiazepam, diazepam, flunitrazepam, flurazepam, hydroxyzin, Ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, meprobamate, metaclazepam, Midazolam, Nitrazepam, Oxazepam, Oxazolam, Prazepam, Temazepam, Tetrazepam, triazolam.

Examples of urologicals are: finasteride.

Examples of varia are: dapiprazole, diethyltoluamide, Lipoic acid.

Examples of venous agents are: aescin, Calcium dobesilate, coumarin, diosmin, rutoside, troxerutin.

Examples of antivirals are: acyclovir, cidofovir, didanosine, famciclovir, foscarnet, ganciclovir, Lamivudine, ritonavir, zalcitabine, zidovudine.

Examples of vitamins are: alfacalcidol; Allithiamine, ascorbic acid, Biotin, calcifediol, calcitriol, colecalciferol, cyanocobalamin, Ergocalciferol, folic acid, Hydroxocobalamin, nicotinamide, pantothenic acid, phytomenadione, pyridoxine, Retinol, riboflavin, thiamine, tocopherol, transcalcifediol.

Examples of cytostatics are: aclarubicin, Altretamine, aminoglutethimide, amsacrine, asparaginase, bleomycin, Buserelin, busulfan, carboplatin, carmustine, chlorambucil, cladribine, Cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, diethylstilbestrol, Docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, Gemcitabine, goserelin, hydroxycarbamide, idarubicin, ifosfamide, lomustine, Melphalan, mercaptopurine, mesna, methotrexate, miltefosine, mitomycin, Mitoxantron, Panorex, Paclitaxel, Plicamycin, Tamoxifen, Tegafur, Thiotepa, tioguanine, topotecan, triptorelin, vinblastine, vincristine, vindesine, Zorubicin.

According to the invention, the active substances mentioned can be in the form a powder, a paste, a film, as a solution, as a melt and are on the backing material preferably applied using the designated adhesion promoter. The described active ingredients and / or active ingredients contained in ginseng can additionally also in the carrier material be introduced.

Under certain circumstances, depending on the type of construction the agent, d. H. Mode of application, application or application of the active ingredients, additionally a delayed release of active ingredient or long-lasting, delayed dosing be achieved.

As already explained above, ensured by the choice of the preferred bonding agent be that yourself on the backing material applied active ingredients contained in ginseng and / or possibly dissolve other active ingredients in the stomach and, if necessary, directly into the Stomach. Next to it further layers of active substance are present, possibly via adhesion promoters are connected to the underlying active substance layer. In this way, a combination of active ingredients can be achieved that dissolve under the conditions of the gastric environment and may have their effect directly in the intestine, while the support material due to its volume increase in Stomach remains and there a satiety effect causes. Depending on the type of active ingredient, it is also possible that this dissolves at least partially in the stomach and so only partially or does not get into the intestine at all. When the carrier is applied by additional Active ingredients are any other treatments feasible. Under other, a sustained release effect can also have a depot effect become. Multilayer active ingredient structures are also conceivable, at which partially detach the adhesive agents in the stomach and partially not solve.

In this way, any Produce drug combinations that, for. T. in the stomach and z. T. develop their effect in the intestine.

Claims (24)

Means for producing a satiety effect and for reducing weight containing at least one active ingredient contained in ginseng and one in gastrointestinal fluids and / or body fluids insoluble or hardly soluble, volumenvergrößerndes Material. Agent according to claim 1, characterized in that the at least An active ingredient contained in ginseng is a ginsenoid. Agent according to claim 1 or 2, characterized in that the at least one active ingredient contained in the ginseng at least partially to the surface of the volume increasing Material is bound. Agent according to one of claims 1 to 3, characterized in that that the at least one active ingredient contained in ginseng by means of an im Stomach at least partially soluble Adhesion promoter to the surface of the volume increasing Material is bound. Means according to one of claims 1 to 4, characterized in that the adhesion promoter is thread-like and / or tissue-like Contains substances. Means according to one of claims 1 to 5, characterized in that the carrier material in compressed Form is present. Means according to one of claims 1 to 6, characterized in that it contains another active ingredient Has wording. Means according to claim 7, characterized in that the usual formulation containing active ingredient Has auxiliaries and additives. Agent according to claim 1, characterized in that the at least an active ingredient contained in ginseng in the volume increasing material is introduced. Agent according to one of claims 1 to 9, characterized in that that it in the form of powders, granules, adsorbates, beatlets, compressed or Tablets, capsules, coated tablets, is present. Agent according to one of claims 1 to 10, characterized in that that there are common excipients and contains additives. Agent according to one of claims 1 to 11, there characterized in that the volume-increasing material contains natural, semi-synthetic or synthetic polymers. Agent according to one of claims 1 to 12, characterized in that that this volume increasing material Contains polysaccharides. Agent according to one of claims 1 to 13, characterized in that that this volume increasing material contains compressed sponge-like substances. Process for the preparation of an agent for production of a saturation effect and for weight loss, characterized in that at least part of the surface one in gastrointestinal fluids and / or body fluids insoluble or poorly soluble, increases in volume Material, if necessary, under pressure and high temperature at least one im Active ingredient containing ginseng is applied. A method according to claim 15, characterized in that the at least one active ingredient contained in ginseng as a ginseng extract is used. A method according to claim 15 or 16, characterized in that that on at least part of the surface of the volume increasing Materials an at least partially stomach-soluble adhesion promoter applied and the at least one active ingredient contained in the ginseng on the Adhesion promoter is applied. Method according to one of claims 15 to 17, characterized in that that the Adhesion promoter layer on the active ingredient contained in the ginseng Layer is applied. Method according to one of claims 15 to 18, characterized in that that the Adhesion promoter in liquid or solid form or in the form of a powder, a paste, a Foil, as a solution, as a melt and / or a combination thereof on the volume-increasing material and / or those containing the active ingredient and / or those contained in the ginseng Active ingredient-containing layer is applied. Method according to one of claims 15 to 19, characterized in that that the at least one ginseng-containing active ingredient in the volume-increasing material is introduced. Method according to one of claims 15 to 20, characterized in that that this volume increasing material in a liquid Soaked ginseng active ingredient becomes. Use of an agent according to any one of claims 1 to 14 to produce a saturation effect and for weight loss. Use of an agent according to any one of claims 1 to 14 for the preparation of a composition for producing a saturation effect and for weight loss. Use of an agent according to any one of claims 1 to 14 for the preparation of a composition for producing a delayed release of at least one active ingredient in ginseng in the stomach and / or intestines.